74.73
Boston Scientific Corp stock is traded at $74.73, with a volume of 13.45M.
It is up +0.82% in the last 24 hours and down -20.62% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$74.12
Open:
$74.82
24h Volume:
13.45M
Relative Volume:
1.04
Market Cap:
$110.83B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
38.54
EPS:
1.9391
Net Cash Flow:
$3.82B
1W Performance:
-2.02%
1M Performance:
-20.62%
6M Performance:
-27.09%
1Y Performance:
-29.59%
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Peering Into Boston Scientific Corp's Recent Short Interest - Benzinga
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider - GlobeNewswire Inc.
Vanguard Group Inc. Buys 1,115,337 Shares of Boston Scientific Corporation $BSX - MarketBeat
Capital Planning Advisors LLC Invests $1.45 Million in Boston Scientific Corporation $BSX - MarketBeat
Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX - MarketBeat
State of New Jersey Common Pension Fund D Purchases 21,386 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments - Finviz
Aberdeen Group plc Has $257.62 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
ABN Amro Investment Solutions Has $54.76 Million Stock Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Stock Slide Tests Support As Outlook And Value Diverge - Yahoo Finance
Reassessing Boston Scientific (BSX) After A 30% Pullback In The Share Price - Yahoo Finance
Can Boston Scientific Corporation stock sustain margin levelsIPO Watch & Risk Controlled Daily Trade Plans - mfd.ru
Does Boston Scientific Corporation stock benefit from AI growthWeekly Trade Analysis & Fast Entry Momentum Trade Alerts - mfd.ru
Atria Investments Inc Purchases 35,788 Shares of Boston Scientific Corporation $BSX - MarketBeat
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference - Finviz
Boston Scientific Corp (NYSE:BSX) Emerges as a Prime GARP Candidate - ChartMill
Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference – Company Announcement - Financial Times
Public Sector Pension Investment Board Purchases 903,448 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Sold by Illinois Municipal Retirement Fund - MarketBeat
Will Boston Scientific Corporation stock hit new highs in YEAR2025 Trade Ideas & Long-Term Growth Stock Strategies - mfd.ru
Is Boston Scientific Corporation still a buy after recent gainsOptions Play & Momentum Based Trading Signals - mfd.ru
Boston Sci’s Farapulse better than thermal ablation at 4 years - bioworld.com
The Top 5 Analyst Questions From Boston Scientific's Q4 Earnings Call - Finviz
Impax Asset Management Group plc Boosts Holdings in Boston Scientific Corporation $BSX - MarketBeat
Aug EndMonth: Can Boston Scientific Corporation sustain its profitabilityMarket Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call - Yahoo Finance
Boston Scientific Board Change Puts Growth And Risk Oversight In Focus - Yahoo Finance
Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus - TechStock²
Boston Scientific Corp (BSX) Stock Price, Trades & News - GuruFocus
Boston Scientific (NYSE:BSX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX) - marketscreener.com
Boston Scientific Farapulse PFA outperforms thermal ablation in study - massdevice.com
Boston Scientific (BSX) Analyst Ratings and Price Targets Update - GuruFocus
Boston Scientific stock price slips again: BSX extends slide as heart-rhythm worries linger - TechStock²
Fraud Investigation Opened: Levi & Korsinsky Investigates Boston Scientific Corporation (BSX) on Behalf of Shareholders - marketscreener.com
Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback - Finviz
Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset - Yahoo Finance
Boston Scientific (NYSE:BSX) Cut to "Hold" at Wall Street Zen - MarketBeat
Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales - TechStock²
Boston Scientific’s Worst Day in 25 Years Surprised Analysts - Bloomberg.com
Boston Scientific to Report Q4 Earnings with Expected Growth - Intellectia AI
Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Chartmill
Bernstein SocGen lowers Boston Scientific stock price target on EP miss - Investing.com
RBC Capital lowers Boston Scientific stock price target to $115 on 2026 guidance - Investing.com
Boston Scientific stock holds Outperform rating at Evercore despite EP miss - Investing.com
Boston Scientific price target lowered to $110 from $125 at Stifel - Yahoo Finance
Boston Scientific’s (BSX) Earnings Implosion Sparks Bullish Options Trade - TipRanks
Boston Scientific (BSX): Analyst Ratings Update and Target Price Changes | BSX Stock News - GuruFocus
Boston Scientific (BSX): Canaccord Genuity Adjusts Price Target, Maintains Buy Rating | BSX Stock News - GuruFocus
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):